<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04591535</url>
  </required_header>
  <id_info>
    <org_study_id>WD-1603-1003</org_study_id>
    <nct_id>NCT04591535</nct_id>
  </id_info>
  <brief_title>PK Study of WD-1603 in Healthy Subjects</brief_title>
  <official_title>An Open Label, Balanced, Randomised, Four-treatment, Four-period, Four-sequence, Single Oral Dose, Crossover PK Study of WD-1603 in Normal, Healthy, Adult Human Subjects Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hong Kong WD Pharmaceutical Co., Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hong Kong WD Pharmaceutical Co., Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label, balanced, randomised, four-treatment, four-period, four-sequence, single oral&#xD;
      dose, crossover Pharmacokinetics study of WD-1603 carbidopa/levodopa extended-release tablets&#xD;
      in normal, healthy, adult human subjects under fed conditions. A single oral dose of (either&#xD;
      Treatment A or B or C or D) carbidopa/levodopa extended release tablets will be administered&#xD;
      to each subject within 5 minutes after completion of standardized vegetarian breakfast under&#xD;
      fed condition in each period as per randomization schedule.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, balanced, randomised, four-treatment, four-period, four-sequence,&#xD;
      single oral dose, crossover Pharmacokinetics study of WD-1603 carbidopa/levodopa&#xD;
      extended-release tablets in normal, healthy, adult human subjects under fed conditions. A&#xD;
      single oral dose of (either Treatment A or B or C or D) carbidopa/levodopa extended release&#xD;
      tablets will be administered to each subject within 5 minutes after completion of&#xD;
      standardized vegetarian breakfast under fed condition in each period as per randomization&#xD;
      schedule.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2020</start_date>
  <completion_date type="Anticipated">March 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 28, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 1 and Day 2</time_frame>
    <description>the maximum plasma concentrations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Day 1 and Day 2</time_frame>
    <description>areas under the plasma concentration</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>WD-1603 (tablet strength 1) single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of carbidopa/levodopa extended release tablets (WD-1603 tablet strength 1) will be administered to each subject within 5 minutes at 30 minutes after serving standardized vegetarian breakfast under fed condition in each period as per randomization schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WD-1603 (tablet strength 2) single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of carbidopa/levodopa extended release tablets (WD-1603 tablet strength 2) will be administered to each subject within 5 minutes at 30 minutes after serving standardized vegetarian breakfast under fed condition in each period as per randomization schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WD-1603 (tablet strength 3) single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of carbidopa/levodopa extended release tablets (WD-1603 tablet strength 3) will be administered to each subject within 5 minutes at 30 minutes after serving standardized vegetarian breakfast under fed condition in each period as per randomization schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WD-1603 (tablet strength 4) single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of carbidopa/levodopa extended release tablets (WD-1603 tablet strength 4) will be administered to each subject within 5 minutes at 30 minutes after serving standardized vegetarian breakfast under fed condition in each period as per randomization schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS</intervention_name>
    <description>WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS</description>
    <arm_group_label>WD-1603 (tablet strength 1) single dose</arm_group_label>
    <arm_group_label>WD-1603 (tablet strength 2) single dose</arm_group_label>
    <arm_group_label>WD-1603 (tablet strength 3) single dose</arm_group_label>
    <arm_group_label>WD-1603 (tablet strength 4) single dose</arm_group_label>
    <other_name>WD-1603</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Normal, healthy adult human volunteers between 18 to 45 years of age (both inclusive).&#xD;
&#xD;
          2. Having a Body Mass Index (BMI) between 18.5 to 29.9 (both inclusive), calculated as&#xD;
             weight in kg / height in m2, a minimum body weight of 50.0 kg.&#xD;
&#xD;
          3. Not having any significant disease or clinically significant abnormal findings during&#xD;
             screening, medical history, clinical examination, laboratory evaluations, 12- lead ECG&#xD;
             and X-ray chest (P/A view) recordings.&#xD;
&#xD;
          4. Able to understand and comply with the study procedures, in the opinion of the&#xD;
             principal investigator.&#xD;
&#xD;
          5. Able to give voluntary written informed consent for participation in the trial.&#xD;
&#xD;
          6. In case of female subjects:&#xD;
&#xD;
        a. Surgically sterilized at least 6 months prior to study participation or If of child&#xD;
        bearing potential is willing to use a suitable and effective double barrier contraceptive&#xD;
        method or intra uterine device during the study.&#xD;
&#xD;
        And b. Serum Pregnancy test must be negative.&#xD;
&#xD;
        g.Female must also be willing to abstain from ovum donation from Screening and for at least&#xD;
        28 days after the last study drug administration.&#xD;
&#xD;
        h.Female subjects of non-childbearing potential must be either post-menopausal&#xD;
        (post-menopausal is defined as being amenorrheic for at least 1 year without another cause&#xD;
        and a follicle-stimulating hormone [FSH] level â‰¥26 IU/L) or surgically sterile&#xD;
        (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation).&#xD;
&#xD;
        i.Male subjects with female sexual partners of childbearing potential must be willing to&#xD;
        use and willing to continue using medically acceptable contraception (true abstinence,&#xD;
        vasectomy, or male condom for subjects plus an additional method of contraception for their&#xD;
        female partners) from dosing until 28 days following the last administration of study drug.&#xD;
&#xD;
        j.Men must also be willing to abstain from sperm donation from Screening and for at least&#xD;
        28 days after the last study drug administration.&#xD;
&#xD;
        k.Subjects should be literate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity or idiosyncratic reaction to Carbidopa or Levodopa or any of&#xD;
             the excipients or any related drug.&#xD;
&#xD;
          2. History or presence of any disease or condition which might compromise the&#xD;
             haemopoietic, renal, hepatic, endocrine, pulmonary, cardiovascular, immunological,&#xD;
             dermatological, gastrointestinal system, and central nervous system with dyskinesia,&#xD;
             depression, suicidal thought, or any other body system.&#xD;
&#xD;
          3. History or presence of ophthalmic diseases such as wide angle glaucoma and ocular&#xD;
             hypertension.&#xD;
&#xD;
          4. Ingestion of a medicine (prescribed &amp; over the counter (OTC) medication including&#xD;
             herbal remedies and MAO inhibitors) at any time within 30 days before dosing in Period&#xD;
             I. In any such case subject selection will be at the discretion of the Principal&#xD;
             Investigator.&#xD;
&#xD;
          5. Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or&#xD;
             NSAIDs induced urticaria.&#xD;
&#xD;
          6. Use of any recreational drugs or history of drug addiction or testing positive in&#xD;
             pre-study drug scans.&#xD;
&#xD;
        g.A recent history of harmful use of alcohol (less than 2 years), i.e. alcohol consumption&#xD;
        of more than 14 standard drinks per week for men and more than 7 standard drinks per week&#xD;
        for women (A standard drink is defined as 360 ml of beer or 150 ml of wine or 45 ml of 40%&#xD;
        distilled spirits, such as rum, whisky, brandy etc) or consumption of alcohol or alcoholic&#xD;
        products within 48 hours prior to dosing in Period I.&#xD;
&#xD;
        h.Smokers, who smoke 10 or more than 10 cigarettes / day or inability to abstain from&#xD;
        smoking during the study.&#xD;
&#xD;
        i.The presence of clinically significant abnormal laboratory values during screening.&#xD;
&#xD;
        j.History or presence of psychiatric disorders. k.A history of difficulty in donating&#xD;
        blood. l.Donation of blood (1 unit or 350 mL) within a period of 90 days prior to the first&#xD;
        dose of study medication.&#xD;
&#xD;
        m.Receipt of an investigational medicinal product or participation in a drug research study&#xD;
        within a period of 90 days prior to the first dose of study medication**.&#xD;
&#xD;
          -  If investigational medicinal product is received within 90 days where there is no&#xD;
             blood loss except safety lab testing, subject can be included considering 10&#xD;
             half-lives duration of investigational medicinal product received.&#xD;
&#xD;
             n.A positive hepatitis screen including hepatitis B surface antigen and/or HCV&#xD;
             antibodies.&#xD;
&#xD;
             o.A positive test result for HIV (1 &amp;/or 2) antibody. p.An unusual diet, for whatever&#xD;
             reason (e.g. low-sodium), for four weeks prior to receiving the study medicine in&#xD;
             period I. In any such case subject selection will be at the discretion of the&#xD;
             Principal Investigator.&#xD;
&#xD;
             q.Consumption of grapefruit or grapefruit products within 72 hours prior to dosing in&#xD;
             period-I.&#xD;
&#xD;
             r.Difficulty in swallowing oral solid dosage form like tablets or capsules. s.Nursing&#xD;
             mothers (females).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shrikrishna Kolte, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lambda Therapeutic Research Limited, Ahmedabad,India</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoxiong Wei, Doctor</last_name>
    <phone>+86-21-6859-9718</phone>
    <email>xiaoxiong.wei@wdpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lambda Therapeutic Research Ltd.</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alpesh J Parmar, Doctor</last_name>
      <phone>+ 91-79-40202020</phone>
      <email>alpeshjparmar@lambda-cro.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 11, 2020</study_first_submitted>
  <study_first_submitted_qc>October 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 11, 2020</last_update_submitted>
  <last_update_submitted_qc>October 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

